Doctor Emmanuel Androulakis

Doctor Emmanuel Androulakis

Royal Brompton and Harefield Hospital, London (United Kingdom of Great Britain & Northern Ireland)

Member of:

Fully trained and certified in the UK, post-CCT Cardiologist subspecialized in Inherited Cardiac Conditions/Sports Cardiology and Multi-Modality Cardiovascular Imaging with a focus on Cardiovascular MRI. Dedicated independent researcher and lead investigator since early stages of career. Current focus on examining pathology discrimination applications of commonly used and advanced techniques of cardiovascular MRI including parametric mapping, and radiomics/machine learning, with the ultimate goal of providing best evidence-based and individualized care in clinical practice.

Presentations

Patterns and clinical significance of non-specific myocardial fibrosis; Evidence from a cohort of young competitive athletes referred to a tertiary referral centre

Event: ESC Preventive Cardiology 2022

Topic: Imaging

Session: Rapid fire abstracts session 2 - Sports Cardiology and Exercise

Access

Long-term outcomes of catheter ablation for ventricular arrhythmias in post- myocarditis patients; Insights from a meta-analysis of current datv

Event: ESC Congress 2021 - The Digital Experience

Topic: Catheter Ablation of Arrhythmias

Session: Arrhythmias e-posters

Access

Cystatin-C as independent predictor of subclinical organ damage in white coat hypertension

Event: ESC CONGRESS 2017

Topic: Haemodynamics, heart and hypertension

Session: Hypertensive organ damage and risk

Access

Linking proinflammatory and procoagulant factors to genetic predisposition of subclinical organ damage in untreated hypertension

Event: ESC CONGRESS 2017

Topic: Basic Science

Session: Cardiovascular care - Biology II

Access

Effects of common genetic variants on preclinical vascular alterations and the possible role of cystatin-C in untreated hypertension

Event: ESC CONGRESS 2017

Topic: Endothelial function

Session: Endothelial dysfunction

Access

Nocturnal hypertension versus non-dipping status in the aim of early detection of preclinical organ damage in newly diagnosed hypertension

Event: ESC CONGRESS 2017

Topic: Hypertension

Session: The brain in hypertension

Access

The impact of renin-angiotensin-aldosterone system genetic variants in subclinical cardiac organ damage and the possible role of cystatin-C in hypertension

Event: ESC CONGRESS 2016

Topic: Hypertrophy, cell cycle and apoptosis

Session: Metabolism and hypertrophy

Access

Association of common genetics variants and their association with vascular organ damage in untreated hypertension

Event: ESC CONGRESS 2016

Topic: Vascular biology, other

Session: Vascular biology and remodelling

Access

The possible role of cystatin-C in subclinical organ damage in white coat hypertension

Event: ESC CONGRESS 2016

Topic: Biomarkers

Session: Biomarkers in CVD

Access

Doctor Emmanuel Androulakis

Biography

Contributor content

Patterns and clinical significance of non-specific myocardial fibrosis; Evidence from a cohort of young competitive athletes referred to a tertiary referral centre

Long-term outcomes of catheter ablation for ventricular arrhythmias in post- myocarditis patients; Insights from a meta-analysis of current datv

Cystatin-C as independent predictor of subclinical organ damage in white coat hypertension

Linking proinflammatory and procoagulant factors to genetic predisposition of subclinical organ damage in untreated hypertension

Effects of common genetic variants on preclinical vascular alterations and the possible role of cystatin-C in untreated hypertension

Nocturnal hypertension versus non-dipping status in the aim of early detection of preclinical organ damage in newly diagnosed hypertension

The impact of renin-angiotensin-aldosterone system genetic variants in subclinical cardiac organ damage and the possible role of cystatin-C in hypertension

Association of common genetics variants and their association with vascular organ damage in untreated hypertension

The possible role of cystatin-C in subclinical organ damage in white coat hypertension

This platform is supported by